SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending as discussions erupt over former President Trump's threats of new tariffs on European nations, stemming from their stance on Greenland and his apparent frustrations regarding the Nobel Peace Prize. This has ignited heated debate among the community, with many expressing concern over potential market instability and strained international relations, while supporters view these actions as beneficial for "America First" economic policies.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after securing a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as a significant validation of its platform technology across potential new disease areas. The community is actively discussing the potential for upfront payments, substantial milestones, and royalties, while also looking for further partnerships, particularly for its advanced COVID-Flu combination vaccine. This recent strategic move, alongside the company's strengthened financial position, is generating optimism about future growth despite ongoing activist investor pressure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is seeing heightened volatility as President Trump's escalating tariff threats against NATO allies, particularly concerning Greenland, spark widespread geopolitical uncertainty. Community sentiment is sharply divided, with some anticipating a deeper market correction while others view the current downturn as a 'buy the dip' opportunity amidst global bond market concerns and a notable rise in precious metal prices. Investors are closely monitoring a potential Supreme Court ruling on tariffs as a key market mover.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is experiencing significant volatility amid escalating geopolitical tensions, notably the US asserting control over Venezuela's oil and ongoing debates surrounding US tariffs, fueling a "flight to quality" narrative for some. The community is actively discussing whether these events, alongside large institutional bond purchases, will continue to boost Treasuries as a safe haven or intensify concerns over US debt and the Federal Reserve's independence.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is currently trending due to news of a strategic acquisition and a recent public offering that sparked extreme volatility. The community is sharply divided between anticipating massive upside driven by its low float and projected profitability, and expressing caution over its significant price swings. Traders are actively debating if this presents a compelling buying opportunity or a cautionary tale, drawing parallels to other high-momentum low-float stocks.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing significant volatility and trending discussions following a critical report alleging financial misconduct, compounded by broader weakness in the tech sector. While many in the community are dismissing the report as rehashed FUD and market manipulation, bulls are highlighting the company's strong AI-powered ad platform and anticipated robust Q4 earnings. This has fueled a sharp debate between those buying the dip and bears reacting to the serious claims, driving notable price swings.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered Compass Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Compass Therapeutics (NASDAQ:CMPX) Trading Down 6.8% - Time to Sell?

Compass Therapeutics (NASDAQ:CMPX) Shares Down 6.8% - Should You Sell...

Compass Therapeutics (NASDAQ:CMPX) Sets New 12-Month High - Time to Buy?

Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year High - Here's Why...

Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $30.00 price target on shares of Compass Therapeutics in a research note on Tuesday...

Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care

William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and reach over $1 billion in global sales.read more...

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have received a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the firm...

Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% - What's Next?

Compass Therapeutics (NASDAQ:CMPX) Trading Up 4.5% - Here's Why...

Are Medical Stocks Lagging  Compass Therapeutics, Inc. (CMPX) This Year?

Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet

The consensus price target hints at a 134.1% upside potential for Compass Therapeutics, Inc. (CMPX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Vivo Capital LLC Purchases 2,487,443 Shares of Compass Therapeutics, Inc. $CMPX

Vivo Capital LLC increased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 70.0% in the second quarter, according to its most recent disclosure with the Securities...

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.14	-$0.08	42.55%	BEAT
Q2 '25	-$0.12	-$0.14	-12.90%	MISSED
Q1 '25	-$0.11	-$0.12	-8.11%	MISSED
Q4 '24	-$0.10	-$0.11	-12.10%	MISSED

CMPX
Compass Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CMPX News

CMPXCompass Therapeutics Inc